Zoledronic acid for Paget's disease of bone

Drugs of Today

Volumn 43, Issue 12, 2007, Pages 879-885

  Maricic, Michael ^a  

^a Catalina Pointe Clinical Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ETIDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; BACKACHE; BONE TURNOVER; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG STRUCTURE; ESOPHAGITIS; FEVER; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOCALCEMIA; KIDNEY DISEASE; KIDNEY FAILURE; MYALGIA; PAGET BONE DISEASE; QUALITY OF LIFE; REVIEW; RISK FACTOR; UVEITIS;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; OSTEITIS DEFORMANS; QUALITY OF LIFE;

EID: 38549115066     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2007.43.12.1141564     Document Type: Review

References (27)

1. van Staa, T.P., Selby, P., Leufkens. H.G. et al. Incidence and natural history of Paget's disease of bone in England and Wales. J Bone Miner Res 2002, 17(3): 465-71.
2. Seton, M., Choi, H.K., Hansen, M.F. et al. Analysis of environmental factors in familial versus sporadic Paget's disease of bone - the New England Registry for Paget's Disease of Bone. J Bone Miner Res 2003, 18(8): 1519-24.
3. Hocking, L.J., Lucas, G.J., Daroszewska, A. et al. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum Mol Genet 2002, 11(22): 2735-9.
4. Roodman, G.D., Windle, J.J. Paget disease of bone. J Clin Invest 2005, 115(2): 200-8.
5. Whyte, M.P., Huges, A.E. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res 2002, 17(1): 26-9.
6. Selby, P.L., Davie, M.W., Ralston, S.H. et al. Bone and Tooth Society of Great Britain, National Association for the relief of Paget's Disease. Guidelines on the management of Paget's disease of bone. Bone 2002, 31(3): 366-73.
7. Langston, A.L., Ralston, S.H. Management of Paget's disease of bone. Rheumatology 2004, 43(8): 955-9.
8. Altman, R.D. Paget's Disease of Bone. In Bone Disease in Rheumatology. Edited by Maricic, M., Gluck, O. Philadelphia: Lippincott, Williams and Wilkins 2005, 177-80.
9. Siris, E., Weinstein, R.S., Altman, R. et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 1996, 81: 961-7.
10. Miller, P.D., Brown, J.P., Siris, E.S. et al. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Am J Med 1999, 106(5): 513-20.
11. Walsh, J.P., Ward, L.C., Stewart, G.O. et al. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Bone 2004, 34(4): 747-54.
12. Green, J.R., Rogers, M.J. Pharmacological profile of zoledronic acid: A highly potent inhibitor of bone resorption. Drug Dev Res 2002, 55: 210-24.
13. Dunford, J.F., Thompson, K., Coxon, F.P. et al. Structure-activity relationships for inhibition of farnesyl disphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonate. J Pharm Exp Ther 2001, 296: 235-42.
14. Viereck, V., Emons, G., Lauck, V. et al. The bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Comm 2002, 291(3): 680-6.
15. Nancollas, G., Tang, R., Guide, S. et al. Mineral binding affinities and zeta potentials of bisphosphonates. J Bone Miner Res 2002, 17: S368.
16. Arden-Cordone, M., Siris, E.S., Lyles, K.W. et al. Antiresorptive effect of a single infusion of ug quantities of zoledronate in Paget's disease of bone. Calcif Tissue Int 1997, 60(5): 415-8.
17. Buckler, H., Fraser, W., Hosking, D. et al. Single infusion of zoledronate in Paget's disease of bone: A placebo-controlled, dose-ranging study. Bone 1999, 24(Suppl. 5): 81S-85S.
18. Reid, I.R., Miller, P., Lyles, K. et al. Comparison of a single infusion of zoledronic aid with risedronate for Paget's disease. N Engl J Med 2005, 353(9): 898-908
19. Hosking, D., Lyles, K., Brown, J.P. et al. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 2007, 22(1): 142-8.
20. Markowitz, G.S., Fine, P.L., Stack, J.L. et al.Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003, 64(1): 281-9.
21. Holick, M.F., Siris, E.S., Binkley, N. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005, 90(6): 3215-24.
22. Ruggiero, S.L., Mehrotra, B., Rosenberg, T.J. et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004, 62(5): 527-34.
23. Black, D.M., Delmas, P.D., Eastell, R. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356(18): 1809-22.
24. Lyles, K.W., Colón-Emeric, C.S., Magaziner, J.S. et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357-68.
25. Early Communication of an Ongoing Safety Review; Bisphosphonates: Alendronate (Dosamax, Fosamax Plus D), Etidronate (Didronel), Ibandronate (Boniva), Pamidronate (Aredia), Risedronate (Actonel, Actonel W/Calcium), Tiludronate (Skelid) and Zoledronic acid (Reclast, Zometa.
26. Gold, D.T., Boisture, J., Shipp, K.M. et al. Paget's disease of bone and quality of life. J Bone Miner Res 1996, 11(12): 1897-904.
27. Groot, A.I.M., Galani, M. et al. Economic evaluation of long term management strategies for Paget's disease of bone. ASBMR Annu Meeting 2005, SA465.